BFAM three-lens brief
Evidence-based stock research on BFAM. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 2% of its 52-week range — deep in the lower band.
- Trading at 2% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- RSI at 29 — technically oversold.
- Underperforming SPY by 18.2pp over 30 days.
- Analyst mean target $71.22 — 37% above current (9 analysts).
BFAM closed at $51.91 (+0.33%) as of 2026-11-12. Market cap: $2.49B. P/E (trailing) 17.4. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $71.22 — 37% above current (9 analysts).. Concerns: trading at 2% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $841.47M, net income -$230.69M, free cash flow $252.94M.
Why three lenses on BFAM, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BFAM across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/BFAM" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BFAM brief"></iframe>